Markets / Mutual funds / Equity ETFs
Mirae Asset Mutual Fund · Index & ETFs fund · Regular plan · Growth
The investment objective of the scheme is to generate returns, before expenses, that are commensurate with the performance of the Nifty 500 Healthcare Total Return Index, subject to tracking error. There is no assurance that the investment objective of the scheme will be achieved.
| Share of fund | 30 Sept 2026 | 31 Aug 2026 | Change |
|---|---|---|---|
| Stocks held | 100.0% | 100.0% | +0.02 |
| Short positions | -0.1% | -2.9% | +2.76 |
| Cash & others | 0.0% | 0.1% | -0.02 |
| Top 10 stocks | 59.5% | 58.7% | +0.77 |
| Number of stocks | 44 | 48 | -4 |
Change is in percentage points. Bought more and cut back list stocks whose share of the fund moved by at least 0.25 points. A share can also move because the price changed, not only because the fund traded.
| Holding | % of fund |
|---|---|
| Sun Pharmaceutical Industries Ltd. INE044A01036 | 10.13% |
| Divi's Laboratories Ltd. INE361B01024 | 8.76% |
| Apollo Hospitals Enterprise Ltd. INE437A01024 | 6.24% |
| Laurus Labs Ltd. INE947Q01028 | 5.72% |
| Cipla Ltd. INE059A01026 | 5.62% |
| Dr. Reddy's Laboratories Ltd. INE089A01031 | 5.58% |
| Torrent Pharmaceuticals Ltd. INE685A01028 | 5.24% |
| Max Healthcare Institute Ltd. INE027H01010 | 5.13% |
| Lupin Ltd. INE326A01037 | 3.66% |
| Aurobindo Pharma Ltd. INE406A01037 | 3.43% |
| Fortis Healthcare Ltd. INE061F01013 | 2.98% |
| Glenmark Pharmaceuticals Ltd. INE935A01035 | 2.61% |
| Alkem Laboratories Ltd. INE540L01014 | 2.31% |
| Zydus Lifesciences Ltd. INE010B01027 | 2.14% |
| Mankind Pharma Ltd. INE634S01028 | 2.10% |
| IPCA Laboratories Ltd. INE571A01038 | 1.98% |
| Biocon Ltd. INE376G01013 | 1.91% |
| Gland Pharma Ltd. INE068V01023 | 1.71% |
| Sai Life Sciences Ltd. INE570L01029 | 1.56% |
| Krishna Institute of Medical Sciences Ltd. INE967H01025 | 1.48% |
| Aster DM Quality Care Ltd. INE914M01019 | 1.38% |
| Neuland Laboratories Ltd. INE794A01010 | 1.36% |
| Wockhardt Ltd. INE049B01025 | 1.30% |
| Acutaas Chemicals Ltd. INE00FF01025 | 1.26% |
| Ajanta Pharma Ltd. INE031B01049 | 1.22% |
| Dr. Lal Path labs Ltd. INE600L01024 | 1.15% |
| Abbott India Ltd. INE358A01014 | 1.04% |
| Piramal Pharma Ltd. INE0DK501011 | 0.95% |
| Granules India Ltd. INE101D01020 | 0.93% |
| Narayana Hrudayalaya Ltd. INE410P01011 | 0.92% |
| Global Health Ltd. INE474Q01031 | 0.90% |
| Onesource Specialty Pharma Ltd. INE013P01021 | 0.89% |
| Glaxosmithkline Pharmaceuticals Ltd. INE159A01016 | 0.85% |
| Anthem Biosciences Ltd. INE0CZ201020 | 0.69% |
| Emcure Pharmaceuticals Ltd. INE168P01015 | 0.60% |
| Natco Pharma Ltd. INE987B01026 | 0.55% |
| Cohance Lifesciences Ltd. INE03QK01018 | 0.54% |
| Vijaya Diagnostic Centre Ltd. INE043W01024 | 0.52% |
| Syngene International Ltd. INE398R01022 | 0.51% |
| Rainbow Children's Medicare Ltd. INE961O01016 | 0.49% |
| Polymedicure Ltd. INE205C01021 | 0.47% |
| Rubicon Research Ltd. INE506V01022 | 0.43% |
| Caplin Point Laboratories Ltd. INE475E01026 | 0.40% |
| Concord Biotech Ltd. INE338H01029 | 0.34% |
| Holding | % of fund |
|---|---|
| Net Receivables / (Payables) | -0.09% |
| Holding | % of fund |
|---|---|
| TREPS | 0.13% |
From the fund house's monthly portfolio (miraeassetmf.co.in), as on 30 Sept 2026. Percentages are of the fund's net assets; short positions are negative. Published about ten days after each month ends.
Volatility: how much the NAV moves, as a yearly figure (higher = bumpier). Worst fall: the biggest drop from a high, in the NAV history we hold (from 6 Nov 2026).
| Fund size (average AUM, July - September 2026) | ₹14.38 cr across all plans |
| Fund house | Mirae Asset Mutual Fund |
| Category | Index & ETFs · Equity ETFs |
| Plan | Regular |
| Option | Growth |
| Expense ratio (TER) | Direct 0.00% · Regular 0.31% (8 Nov 2026) |
| Minimum investment | On exchange in multiple of 1 unit. With AMC: In multiples of 5,000 units |
| Scheme code (AMFI) | 154169 |
| ISIN | INF769K01QA6 |
| NAV date | 6 Nov 2026 |
Scheme details from the fund's scheme summary document filed with AMFI; expense ratios from AMFI's daily filings.
Information only, not investment advice.
₹22.0706 as of 6 Nov 2026, from AMFI's official NAV data.
Returns appear once enough NAV history is available.
Both invest in the same portfolio. Direct plans are bought straight from the fund house and pay no distributor commission, so their expenses are lower and their NAV grows slightly faster.